Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Arvinas Appoints Andrew Saik As Chief Financial Officer and Treasurer

PUBLIC · ARVNJun 24, 2024•almost 2 years ago

Position

Treasurer

Company

Arvinas

Andrew Saik

New HavenBiotechnologyHealth CareTherapeuticsresearch

Description

Arvinas, Inc announced the appointment of Andrew Saik as the Chief Financial Officer and Treasurer. Mr Saik brings over 20 years of biopharma finance experience to the company, having previously served in leadership roles at Intercept Pharmaceuticals, Inc, Vyne Therapeutics Inc, PDS Biotechnology, Corp, Vertice Pharma, LLC, and Auxilium Pharmaceuticals, Inc.

Company Information

Company

Arvinas

Location

5 Science Park

New Haven, Kentucky, United States

About

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer; and vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Arvinas's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months